SOPHiA GENETICS (SOPH) CEO 10b5-1 sale of 8,500 shares

Rhea-AI Filing Summary

SOPHiA GENETICS SA Chief Executive Officer Jurgi Camblong sold 8,500 ordinary shares in an open-market transaction. The sale took place at a weighted average price of $5.0872 per share under a duly adopted Rule 10b5-1(c) trading plan. Following this transaction, he reports direct ownership of 3,633,981 ordinary shares.

Insights

Insider transactions analyst

CEO executes small 10b5-1 planned sale while retaining a large position.

CEO Jurgi Camblong completed an open-market sale of 8,500 SOPHiA GENETICS SA ordinary shares at a weighted average price of $5.0872. The trade is coded as an open-market sale and classified as a non-derivative transaction.

The filing notes the sale was made under a duly adopted Rule 10b5-1(c) trading plan, indicating it was pre-planned rather than opportunistic. After the sale, Camblong directly holds 3,633,981 ordinary shares, so the disposed amount represents a small portion of his reported holdings.

Because the transaction is pre-scheduled and relatively small compared with his remaining stake, it generally reads as routine liquidity management rather than a major change in insider exposure. Future company filings may provide additional context on any subsequent trades under the same trading plan.

Insider Trade Summary 10b5-1

Net Seller: 8,500 shares ($43,241)

Net Sell 1 txn

Insider Camblong Jurgi

Role Chief Executive Officer

Sold 8,500 shs ($43K)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares	8,500	$5.0872	$43K

Holdings After Transaction: Ordinary Shares — 3,633,981 shares (Direct, null)

Footnotes (1)

1. Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c). The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.72 to $5.49, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Key Figures

Shares sold: 8,500 shares Weighted average sale price: $5.0872 per share Post-transaction holdings: 3,633,981 shares +2 more

5 metrics

Shares sold 8,500 shares Open-market sale of ordinary shares

Weighted average sale price $5.0872 per share Price for 8,500-share sale

Post-transaction holdings 3,633,981 shares Ordinary shares held directly after sale

Price range of trades $4.72–$5.49 per share Range of individual sale prices

Transaction date 2026-05-11 Date of open-market sale

Key Terms

Rule 10b5-1(c), weighted average price, open-market sale, ordinary shares

4 terms

Rule 10b5-1(c) regulatory

"Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c)."

Rule 10b5-1(c) is an SEC guideline that lets company insiders set up a written, pre-planned schedule to buy or sell their company stock when they are not in possession of material, nonpublic information. For investors, it matters because such plans can reduce the appearance of insider trading by separating decisions from inside knowledge—like putting your trades on autopilot—while also requiring scrutiny since pre-planned trades can still affect market confidence and share value.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

ordinary shares financial

""security_title": "Ordinary Shares""

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Camblong Jurgi

(Last) (First) (Middle)

C/O SOPHIA GENETICS SA

LA PIECE 12

(Street)

ROLLE 1180

(City) (State) (Zip)

SWITZERLAND

(Country)

2. Issuer Name and Ticker or Trading Symbol
SOPHiA GENETICS SA [ SOPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	05/11/2026		S		8,500(1)	D	$5.0872(2)	3,633,981	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c).

2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.72 to $5.49, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

	/s/ Elimara Brunetto as Attorney-in- Fact for Jurgi Camblong	05/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did SOPHiA GENETICS (SOPH) report for CEO Jurgi Camblong?

CEO Jurgi Camblong reported selling 8,500 SOPHiA GENETICS ordinary shares in an open-market transaction. The sale used a weighted average price of $5.0872 per share and was executed under a pre-established Rule 10b5-1(c) trading plan.

At what price did SOPHiA GENETICS CEO Jurgi Camblong sell his shares?

Jurgi Camblong sold his SOPHiA GENETICS ordinary shares at a weighted average price of $5.0872. The filing notes multiple trades occurred in a range from $4.72 to $5.49 per share, with the reported price reflecting their volume-weighted average.

How many SOPHiA GENETICS shares does the CEO hold after the reported sale?

After the reported transaction, CEO Jurgi Camblong directly holds 3,633,981 SOPHiA GENETICS ordinary shares. This figure reflects his position following the 8,500-share open-market sale disclosed in the Form 4 insider trading report.

Was the SOPHiA GENETICS CEO share sale made under a Rule 10b5-1 trading plan?

Yes. The filing states the share sale was made pursuant to a duly adopted trading plan under Rule 10b5-1(c). Such plans allow insiders to pre-schedule trades, helping separate personal liquidity needs from day-to-day market timing decisions.

What does the price range disclosure mean in the SOPHiA GENETICS Form 4 filing?

The filing explains the 8,500 shares were sold in multiple transactions between $4.72 and $5.49 per share. The reported $5.0872 figure is a weighted average, and the CEO offers to provide full trade-by-trade pricing details upon written request.